Risperidone in the treatment of mixed state bipolar patients: Results from a 24-week, multicenter, open-label study in Korea |
| |
Authors: | Young Sup Woo md Won-Myong Bahk md Duk-In Jon md Sang-Keun Chung md Sang-Yeol Lee md Yong Min Ahn md Chi-Un Pae md Hyun-Sang Cho md Jeong-Gee Kim md Tae-Yeon Hwang md Hong-Seok Lee md Kyung Joon Min md Kyung-Uk Lee md Bo-Hyun Yoon md |
| |
Affiliation: | Department of Psychiatry, College of Medicine, Catholic University of Korea,;Department of Psychiatry, Seoul National University Hospital,;Department of Psychiatry, Yonsei University, College of Medicine,;Department of Neuropsychiatry, College of Medicine, Chung-Ang University, Seoul,;Department of Psychiatry, College of Medicine, Hallym University, Anyang,;Department of Psychiatry, Chonbuk National University Medical School, Jeonju,;Department of Neuropsychiatry, College of Medicine, WonKwang University, Iksan,;Department of Psychiatry, Maryknoll Hospital, Busan,;Yong-In Mental Hospital, Yongin and;Naju National Hospital, Naju, Korea |
| |
Abstract: | Aims: The goal of the present study was to evaluate the efficacy of risperidone combined with mood stabilizers for treating bipolar mixed state. Methods: The present study was a 24-week, open-label, combination, prospective investigation of the efficacy of risperidone in combination with mood stabilizers. Risperidone (1–6 mg/day) was given in combination with mood stabilizers in flexible doses according to clinical response and tolerability for 114 patients in mixed or manic episode. Results: Forty-four patients met our criteria for mixed state bipolar disorder and 70 met the criteria for pure mania. Mean age for the subjects was 39.0 ± 11.0 years and 55.3% were female. The combination of risperidone with mood stabilizers significantly improved the scores on the Young Mania Rating Scale (YMRS), 17-item Hamilton Rating Scale for Depression (HAMD), 18-item Brief Psychiatric Rating Scale (BPRS), Global Assessment Scale (GAS), and Clinical Global Impression Scale for use in bipolar illness Severity (CGI-BP) at 24 weeks ( P < 0.0001). Analysis of the YMRS, BPRS, GAS, and CGI-BP scores showed significant improvement in both the manic and mixed groups. The rate of response in YMRS scores was 84.2% ( n = 96) and the rate of YMRS remission was 77.2% ( n = 88) at week 24 in the total population. Seventy-four patients met both YMRS ≤ 12 and HAMD ≤ 7 at week 24 (64.9%). Risperidone was well tolerated, and adverse events were mostly mild. Conclusion: The combination of risperidone with mood stabilizers was an effective and safe treatment for manic symptoms and coexisting depressive symptoms of bipolar disorder. |
| |
Keywords: | bipolar disorder mixed state mood stabilizer risperidone |
|
|